Boston Scientific Sets $2 Billion Accelerated Stock Buyback

By Colin Kellaher


Boston Scientific has signed a $2 billion accelerated share-repurchase agreement with JPMorgan Chase as part of the medical-technology company's $5 billion stock-buyback program.

Boston Scientific on Monday said it expects an initial delivery of about 30.4 million shares, representing about 80% of the stock covered by the agreement, adding that it expects to complete the accelerated buyback by June 30.

The Marlborough, Mass., company, which had nearly 1.49 billion shares outstanding as of April 29, sports a market capitalization topping $78 billion.

Boston Scientific said it will still have $3 billion available under its share-repurchase authorization upon completion of the accelerated buyback.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

May 18, 2026 07:42 ET (11:42 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center